Leptin receptor gene polymorphisms in patients with post-transplant diabetes mellitus

Abstract

Post-transplant diabetes mellitus (PTDM) is a metabolic complication that often occurs after kidney transplantation. Factors that increase the risk of this complication are currently being researched, including polymorphisms in genes affecting carbohydrate-lipid metabolism. Leptin is a hormone that affects appetite and adipose tissue and plays an important role in regulating insulin secretion as well as glucose and lipid metabolism. The aim of this study was to examine the association between leptin receptor gene polymorphisms and the development of post-transplant diabetes mellitus. The study was carried out in a group of 201 patients who underwent kidney transplantation. The follow-up period was 12 months. PTDM was diagnosed in 35 patients. There were no statistically significant differences in the distribution of the LEPR rs1137100 and LEPR rs1805094 polymorphisms between patients with and without PTDM. Analysing the LEPR gene rs1137101 polymorphism, we observed in patients with PTDM an increased frequency of GG allele carriers (GG vs AA; OR 3.36; 95% CI (0.99–11.46), p = 0.044). Multivariate regression analysis confirmed that female sex, advanced age, increased BMI and a higher number of LEPR rs1137101 G alleles were independent risk factors for PTDM development. The risk of PTDM development was almost 3.5 times greater in LEPR rs1137101 G allele carriers than in AA homozygotes (GG + AG vs AA; OR 3.48; 95%CI (1.09–11.18), p = 0.035). The results suggest that patients after kidney transplantation with the LEPR gene rs1137101 G allele have an increased risk of post-transplant diabetes development.

HDL-C and creatinine levels at 1 month are associated with patient 12-month survival rate after kidney transplantation

“…Similarly, our study demonstrated that the blood glucose of patients carrying *3/*3 was significantly higher than that in the perioperative period. Diabetes after kidney transplantation is common [27]. Our study also demonstrated that patients carrying CYP3A5 *3/*3 had a significant increase in blood glucose 1 month after transplantation, but this did not occur in the *1/*1 and *1/*3 groups.…”